This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
Svend Albaek and Raphaël De Coninck explore the proposed use of “dynamic capabilities” analysis in European merger control as authorities increasingly focus on...
Under these circumstances, it is however not entirely clear how the future competitive landscape will look like, merger effects cannot be modelled with a high...
In the rapidly evolving digital economy, navigating the legal and regulatory aspects issues is a complex task. Gaining access to the latest research,...
CRA is a proud sponsor of the symposium bringing together early-career economists to foster discussion and dissemination of research in all areas of industrial...
